Paper2706751
D-Arg-[Hyp3-D-Phe7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock.
Wilson DD and 5 others. Circ Shock, 1989. Cited by 56 papers, by iCite.
Cite this record
ConductScience Library. D-Arg-[Hyp3-D-Phe7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock. Papers, record 2706751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2706751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- D-Arg-[Hyp3-D-Phe7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Analgesics | Major topic |
| Bradykinin | Major topic |
| Shock, Septic | Major topic |
| Animals | |
| Disease Models, Animal | |
| Hemodynamics | |
| Lipopolysaccharides | |
| Male | |
| Prostaglandins F | |
| Radioimmunoassay | |
| Rats | |
| Rats, Inbred Strains | |
| Thromboxane B2 |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 30945263 | Bradykinin increases BP in endotoxemic rat: functional and biochemical evidence of angiotensin II AT1 /bradykinin B2 receptor heterodimerization. | Br J Pharmacol | 2019 | https://conductscience.org/library/papers/30945263 | PubMed |
| 22352684 | PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis. | Cardiovasc Hematol Agents Med Chem | 2012 | https://conductscience.org/library/papers/22352684 | PubMed |
| 18425495 | Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors. | J Mol Med (Berl) | 2008 | https://conductscience.org/library/papers/18425495 | PubMed |
| 10510436 | Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation. | Br J Pharmacol | 1999 | https://conductscience.org/library/papers/10510436 | PubMed |
| 7620716 | Comparative study of endotoxin-induced hypotension in kininogen-deficient rats with that in normal rats. | Br J Pharmacol | 1995 | https://conductscience.org/library/papers/7620716 | PubMed |
| 7542531 | Regulation of prostaglandin production by nitric oxide; an in vivo analysis. | Br J Pharmacol | 1995 | https://conductscience.org/library/papers/7542531 | PubMed |
| 2234103 | A bradykinin antagonist inhibits carrageenan edema in rats. | Naunyn Schmiedebergs Arch Pharmacol | 1990 | https://conductscience.org/library/papers/2234103 | PubMed |
| 1958169 | Does bradykinin play a role in the cardiac antiischemic effect of the ACE-inhibitors? | Basic Res Cardiol | 1991 | https://conductscience.org/library/papers/1958169 | PubMed |
| 1878745 | Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg9-bradykinin: possible role of interleukin-1. | Br J Pharmacol | 1991 | https://conductscience.org/library/papers/1878745 | PubMed |
| 1373271 | Activation of the contact system in lethal hypotensive bacteremia in a baboon model. | Am J Pathol | 1992 | https://conductscience.org/library/papers/1373271 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2706751
GET https://conductscience.org/api/papers/v1/2706751/authors